Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation

TEL-JAK2 fusion proteins, which are a result of t(9; 12)(p24; p13) translocations associated with human leukemia, activate Stat5 in vitro and in vivo and cause a myelo- and lymphoproliferative disease in a murine bone marrow transplant model. We report that Socs-1, a member of the SOCS family of end...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and cellular biology 2001-05, Vol.21 (9), p.3547-3557
Main Authors: Frantsve, J, Schwaller, J, Sternberg, D W, Kutok, J, Gilliland, D G
Format: Article
Language:English
Subjects:
JAK2 kinase
proteasomes
Socs-1 gene
TEL protein
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 3557
container_issue 9
container_start_page 3547
container_title Molecular and cellular biology
container_volume 21
creator Frantsve, J
Schwaller, J
Sternberg, D W
Kutok, J
Gilliland, D G
description TEL-JAK2 fusion proteins, which are a result of t(9; 12)(p24; p13) translocations associated with human leukemia, activate Stat5 in vitro and in vivo and cause a myelo- and lymphoproliferative disease in a murine bone marrow transplant model. We report that Socs-1, a member of the SOCS family of endogenous inhibitors of JAKs and STATs, inhibits transformation of Ba/F3 cells by TEL-JAK2 but has no effect on Ba/F3 cells transformed by BCR-ABL TEL-ABL, or TEL-platelet-derived growth factor receptor beta. TEL-JAK2, in addition to activating Stat5, associates with Shc and Grb2 and induces activation of Erk2, and expression of Socs-1 inhibits engagement of each of these signaling molecules. TEL-JAK2 kinase activity is inhibited by Socs-1, as assessed by in vitro kinase assays. In addition, Socs-1 induces proteasomal degradation of TEL-JAK2. Mutational analysis indicates that the SOCS box of Socs-1 is required for proteasomal degradation and for abrogation of growth of TEL-JAK2-transformed cells. Furthermore, murine bone marrow transplant assays demonstrate that expression of Socs-1 prolongs latency of TEL-JAK2-mediated disease in vivo. Collectively, these data indicate that Socs-1 inhibits TEL-JAK2 in vitro and in vivo through inhibition of kinase activity and induction of TEL-JAK2 protein degradation.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_17847791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17847791</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_178477913</originalsourceid><addsrcrecordid>eNqNjsFOwzAQRH0AiUL5hz1xs-Q0qKbHqhQVSiUkcq9ce9MsSrzF6yDxPfwoAbXiymnm8PRmztTITKzRtjTTC3Up8maMmc5MOVJfr-xFF_AYG9pRFqiWz_ppvp7oDQZyGQNUyUWpOXUuE0fgGlY4dD4wYSYPC2xbgdwk7vfNSXQkf0ywpugEYe4zfVD-BBfDgIXen6iXxBmdcId_q_e4Ty78To7Vee1awetjXqmbh2W1WOlD4vceJW87Ej-8cBG5l21h726tnRXlv8FvV2de5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17847791</pqid></control><display><type>article</type><title>Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation</title><source>Open Access: PubMed Central</source><creator>Frantsve, J ; Schwaller, J ; Sternberg, D W ; Kutok, J ; Gilliland, D G</creator><creatorcontrib>Frantsve, J ; Schwaller, J ; Sternberg, D W ; Kutok, J ; Gilliland, D G</creatorcontrib><description>TEL-JAK2 fusion proteins, which are a result of t(9; 12)(p24; p13) translocations associated with human leukemia, activate Stat5 in vitro and in vivo and cause a myelo- and lymphoproliferative disease in a murine bone marrow transplant model. We report that Socs-1, a member of the SOCS family of endogenous inhibitors of JAKs and STATs, inhibits transformation of Ba/F3 cells by TEL-JAK2 but has no effect on Ba/F3 cells transformed by BCR-ABL TEL-ABL, or TEL-platelet-derived growth factor receptor beta. TEL-JAK2, in addition to activating Stat5, associates with Shc and Grb2 and induces activation of Erk2, and expression of Socs-1 inhibits engagement of each of these signaling molecules. TEL-JAK2 kinase activity is inhibited by Socs-1, as assessed by in vitro kinase assays. In addition, Socs-1 induces proteasomal degradation of TEL-JAK2. Mutational analysis indicates that the SOCS box of Socs-1 is required for proteasomal degradation and for abrogation of growth of TEL-JAK2-transformed cells. Furthermore, murine bone marrow transplant assays demonstrate that expression of Socs-1 prolongs latency of TEL-JAK2-mediated disease in vivo. Collectively, these data indicate that Socs-1 inhibits TEL-JAK2 in vitro and in vivo through inhibition of kinase activity and induction of TEL-JAK2 protein degradation.</description><identifier>ISSN: 0270-7306</identifier><language>eng</language><subject>JAK2 kinase ; proteasomes ; Socs-1 gene ; TEL protein</subject><ispartof>Molecular and cellular biology, 2001-05, Vol.21 (9), p.3547-3557</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Frantsve, J</creatorcontrib><creatorcontrib>Schwaller, J</creatorcontrib><creatorcontrib>Sternberg, D W</creatorcontrib><creatorcontrib>Kutok, J</creatorcontrib><creatorcontrib>Gilliland, D G</creatorcontrib><title>Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation</title><title>Molecular and cellular biology</title><description>TEL-JAK2 fusion proteins, which are a result of t(9; 12)(p24; p13) translocations associated with human leukemia, activate Stat5 in vitro and in vivo and cause a myelo- and lymphoproliferative disease in a murine bone marrow transplant model. We report that Socs-1, a member of the SOCS family of endogenous inhibitors of JAKs and STATs, inhibits transformation of Ba/F3 cells by TEL-JAK2 but has no effect on Ba/F3 cells transformed by BCR-ABL TEL-ABL, or TEL-platelet-derived growth factor receptor beta. TEL-JAK2, in addition to activating Stat5, associates with Shc and Grb2 and induces activation of Erk2, and expression of Socs-1 inhibits engagement of each of these signaling molecules. TEL-JAK2 kinase activity is inhibited by Socs-1, as assessed by in vitro kinase assays. In addition, Socs-1 induces proteasomal degradation of TEL-JAK2. Mutational analysis indicates that the SOCS box of Socs-1 is required for proteasomal degradation and for abrogation of growth of TEL-JAK2-transformed cells. Furthermore, murine bone marrow transplant assays demonstrate that expression of Socs-1 prolongs latency of TEL-JAK2-mediated disease in vivo. Collectively, these data indicate that Socs-1 inhibits TEL-JAK2 in vitro and in vivo through inhibition of kinase activity and induction of TEL-JAK2 protein degradation.</description><subject>JAK2 kinase</subject><subject>proteasomes</subject><subject>Socs-1 gene</subject><subject>TEL protein</subject><issn>0270-7306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNqNjsFOwzAQRH0AiUL5hz1xs-Q0qKbHqhQVSiUkcq9ce9MsSrzF6yDxPfwoAbXiymnm8PRmztTITKzRtjTTC3Up8maMmc5MOVJfr-xFF_AYG9pRFqiWz_ppvp7oDQZyGQNUyUWpOXUuE0fgGlY4dD4wYSYPC2xbgdwk7vfNSXQkf0ywpugEYe4zfVD-BBfDgIXen6iXxBmdcId_q_e4Ty78To7Vee1awetjXqmbh2W1WOlD4vceJW87Ej-8cBG5l21h726tnRXlv8FvV2de5g</recordid><startdate>20010501</startdate><enddate>20010501</enddate><creator>Frantsve, J</creator><creator>Schwaller, J</creator><creator>Sternberg, D W</creator><creator>Kutok, J</creator><creator>Gilliland, D G</creator><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20010501</creationdate><title>Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation</title><author>Frantsve, J ; Schwaller, J ; Sternberg, D W ; Kutok, J ; Gilliland, D G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_178477913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>JAK2 kinase</topic><topic>proteasomes</topic><topic>Socs-1 gene</topic><topic>TEL protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frantsve, J</creatorcontrib><creatorcontrib>Schwaller, J</creatorcontrib><creatorcontrib>Sternberg, D W</creatorcontrib><creatorcontrib>Kutok, J</creatorcontrib><creatorcontrib>Gilliland, D G</creatorcontrib><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Molecular and cellular biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frantsve, J</au><au>Schwaller, J</au><au>Sternberg, D W</au><au>Kutok, J</au><au>Gilliland, D G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation</atitle><jtitle>Molecular and cellular biology</jtitle><date>2001-05-01</date><risdate>2001</risdate><volume>21</volume><issue>9</issue><spage>3547</spage><epage>3557</epage><pages>3547-3557</pages><issn>0270-7306</issn><abstract>TEL-JAK2 fusion proteins, which are a result of t(9; 12)(p24; p13) translocations associated with human leukemia, activate Stat5 in vitro and in vivo and cause a myelo- and lymphoproliferative disease in a murine bone marrow transplant model. We report that Socs-1, a member of the SOCS family of endogenous inhibitors of JAKs and STATs, inhibits transformation of Ba/F3 cells by TEL-JAK2 but has no effect on Ba/F3 cells transformed by BCR-ABL TEL-ABL, or TEL-platelet-derived growth factor receptor beta. TEL-JAK2, in addition to activating Stat5, associates with Shc and Grb2 and induces activation of Erk2, and expression of Socs-1 inhibits engagement of each of these signaling molecules. TEL-JAK2 kinase activity is inhibited by Socs-1, as assessed by in vitro kinase assays. In addition, Socs-1 induces proteasomal degradation of TEL-JAK2. Mutational analysis indicates that the SOCS box of Socs-1 is required for proteasomal degradation and for abrogation of growth of TEL-JAK2-transformed cells. Furthermore, murine bone marrow transplant assays demonstrate that expression of Socs-1 prolongs latency of TEL-JAK2-mediated disease in vivo. Collectively, these data indicate that Socs-1 inhibits TEL-JAK2 in vitro and in vivo through inhibition of kinase activity and induction of TEL-JAK2 protein degradation.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 0270-7306
ispartof Molecular and cellular biology, 2001-05, Vol.21 (9), p.3547-3557
issn 0270-7306
language eng
recordid cdi_proquest_miscellaneous_17847791
source Open Access: PubMed Central
subjects JAK2 kinase
proteasomes
Socs-1 gene
TEL protein
title Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A30%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Socs-1%20Inhibits%20TEL-JAK2-Mediated%20Transformation%20of%20Hematopoietic%20Cells%20through%20Inhibition%20of%20JAK2%20Kinase%20Activity%20and%20Induction%20of%20Proteasome-Mediated%20Degradation&rft.jtitle=Molecular%20and%20cellular%20biology&rft.au=Frantsve,%20J&rft.date=2001-05-01&rft.volume=21&rft.issue=9&rft.spage=3547&rft.epage=3557&rft.pages=3547-3557&rft.issn=0270-7306&rft_id=info:doi/&rft_dat=%3Cproquest%3E17847791%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_178477913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17847791&rft_id=info:pmid/&rfr_iscdi=true